Pfizer, BioNTech seek US emergency nod for Covid-19 vaccine in adolescents

Pfizer, BioNTech seek US emergency nod for Covid-19 vaccine in adolescents
Pfizer, BioNTech seek US emergency nod for Covid-19 vaccine in adolescents

Hello and welcome to the details of Pfizer, BioNTech seek US emergency nod for Covid-19 vaccine in adolescents and now with the details

Nevin Al Sukari - Sana'a - The vaccine is currently authorised for emergency use in the United States for people aged 16 and up. The companies said yesterday that they requested an expansion of the authorisation from the US Food and Drug Administration to include the younger age group. — Reuters pic

Subscribe to our Telegram channel for the latest updates on news you need to know.


NEW YORK, April 10 — Pfizer Inc and its German partner BioNTech SE yesterday asked US regulators to allow the emergency use of their vaccine in adolescents aged 12 to 15.

The vaccine is currently authorised for emergency use in the United States for people aged 16 and up. The companies said yesterday that they requested an expansion of the authorisation from the US Food and Drug Administration to include the younger age group.

In March, the drugmakers said the vaccine was found to be safe, effective and produced robust antibody responses in 12 — to 15-year olds in a clinical trial.

It is unclear how long the regulator will take to review the data from the trial, although US Centres for Disease Control director Rochelle Walensky told ABC News on Thursday she expects the vaccine to be authorised for 12 — to 15-year-olds by mid-May.

Dr Janet Woodcock, acting commissioner of the FDA, said on Twitter the agency would review Pfizer’s request “as expeditiously as possible”, but cannot predict how long data evaluation would take.

The regulator said it does not plan to hold a meeting of the independent advisory board that recommended the vaccine’s initial authorisation, for expanding its use in adolescents.

Moderna Inc and Johnson & Johnson are also testing their vaccines in 12 — to 18-year olds, and data from Moderna’s trial could come soon.

Pfizer and Moderna have also launched trials in even younger children, aged six months to 11 years old. Both companies have said they hope to be able to vaccinate children under 11 as soon as early 2022.

Inoculating children and young people is considered a critical step toward reaching herd immunity and taming the pandemic, according to many experts.

Pfizer and BioNtech said they plan to ask other regulatory authorities globally to allow the use of their vaccine in 12 — to 15-year olds in the coming days. ­— Reuters

These were the details of the news Pfizer, BioNTech seek US emergency nod for Covid-19 vaccine in adolescents for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV War criminal Radovan Karadzic to serve rest of prison sentence in UK
NEXT Ruling paves way for longer sentence in George Floyd’s death